C17ORF39 Polyclonal Antibody, Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-9839R-Cy7 |
| Product Name | C17ORF39 Polyclonal Antibody, Cy7 Conjugated |
| Applications |
WB
IF(IHC-P)
|
| Reactivity | Rat |
| Predicted Reactivity | Human, Mouse, Cow, Horse |
| Specifications | |
| Conjugation | Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human C17ORF39 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 79018 |
| Synonyms | Uncharacterized protein C17orf39; Chromosome 17 open reading frame 39; Hypothetical protein LOC79018; MGC3048; GID4_HUMAN. |
| Background | C17orf39 is a 300 amino acid protein that is encoded by a gene mapping to human chromosome 17. Chromosome 17 makes up over 2.5% of the human genome with about 81 million bases encoding over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes. Chromosome 17 is also linked to neurofibromatosis, a condition characterized by neural and epidermal lesions, and dysregulated Schwann cell growth. Alexander disease, Birt-Hogg-Dube syndrome and Canavan disease are also associated with chromosome 17. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
Frequently asked questions
Which applications is C17ORF39 Polyclonal Antibody, Cy7 Conjugated (bs-9839R-Cy7) validated for, and at what dilution?
bs-9839R-Cy7 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does C17ORF39 Polyclonal Antibody, Cy7 Conjugated (bs-9839R-Cy7) react with?
Tested reactivity: Rat. Predicted reactivity (expected from sequence homology but not yet tested): Human, Mouse, Cow, Horse.
How should bs-9839R-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise C17ORF39 Polyclonal Antibody, Cy7 Conjugated (bs-9839R-Cy7)?
KLH conjugated synthetic peptide derived from human C17ORF39
What are the excitation and emission wavelengths of the Cy7 conjugate (bs-9839R-Cy7)?
Cy7 on bs-9839R-Cy7: excitation / emission 743nm/767nm.